The $129 Billion Blood Problem Nobody Could Solve — Until Now

Coagulation Sciences (New York) is a medical device company that has developed the Multiple Coagulation Test System (MCTS), a point-of-care platform designed to rapidly and personally guide treatment of major bleeding. Using less than a teaspoon of blood, a single-use pre-filled cartridge delivers 18 results in about 10 minutes, simultaneously testing multiple therapies to identify the exact treatment that will correct a patient's clotting — the only platform that does so — and flagging when transfusions are unnecessary, addressing a problem where ~45% of transfusions are likely avoidable, hospitals lose ~$800 per unnecessary transfusion under bundled payments (>$129B in US costs), and over 5% of surgical patients with major bleeding die within 30 days. Backed by $6.1M in angel funding, the company has built three device generations, completed 12 supporting studies including a 98-patient Mayo Clinic feasibility study in cardiac surgery, held three FDA pre-submission meetings with agreement on a De Novo pathway, and holds 33 patents (19 active through 2039) across major markets. Led by founder and CEO Dr. Sheldon Goldstein, a cardiac anesthesiologist with 30+ years managing bleeding patients, and supported by prominent scientific and business advisors, it is now raising a $20M Series A to fund GMP system build, a clinical trial, and FDA submission over ~15 quarters to commercialization, projecting a razor-blade business model (~90% of revenue from 80%+ margin cartridges) reaching ~$103M revenue and ~$47M EBITDA by year five in a point-of-care coagulation market projected to hit $5.2B by 2034, with exits envisioned via acquisition in a space with precedent deals up to $2.8B.